A multitarget real-time PCR (MRT-PCR) for detection of
Chlamydia trachomatis is a bacterial infection of global public health significance (10) . It is an intracellular pathogen with 15 serotypes. It causes trachoma (serotypes A, B, B 1 , and C), lymphogranuloma venereum (serotypes L 1 , L 2 , and L 3 ), and oculogenital infections (serotypes D to K). There are many highly conserved nucleotide sequences in different chromosomal genes and in the cryptic plasmid (CP) of C. trachomatis. These sequences are used as targets for nucleic acid amplification tests (NAATs). NAATs have surpassed cell culture and antigen detection for the diagnosis of C. trachomatis infections due to their enhanced sensitivities.
A large number of in-house NAATs for the detection of C. trachomatis have been reported (16) . The majority of these are gel based. A few non-gel-based NAATs have also been described, i.e., a Q␤ replicase-amplified assay (2) and PCR-enzyme immunoassays (4, 11, 21) . All previously reported inhouse NAATs are manual and use open systems with separate steps for amplification and amplicon analysis. Due to the risk of contamination and a lack of automation, these assays are inappropriate for diagnostic laboratories with high workloads. Real-time PCR is performed in a closed system, amplification and detection of target are done in a single step, and there is the potential for automation. Real-time PCR has been used for pharmacodynamic studies for C. trachomatis (19, 23) . Two real-time PCR assays for the detection of C. trachomatis have also been described (8, 13) . Both these assays used the SYBR green technology in the LightCycler system (Roche Molecular Systems, Inc., Pleasanton, CA) and were used for the qualitative detection of C. trachomatis. Roche Molecular Systems, GEN-PROBE Inc. (San Diego, CA), BD Diagnostics (Sparks, MD), and artus GmbH (Hamburg, Germany) are the four major commercial companies which supply NAATs for the detection of C. trachomatis in Europe. At present, artus GmbH is the only commercial company that provides an assay for the quantification of C. trachomatis in clinical samples.
A single gene of C. trachomatis per amplification reaction was targeted in all of the in-house and commercial assays mentioned above. The targets of amplification were the CP, the major outer membrane protein (MOMP) gene, the 23S rRNA gene, and the cysteine-rich outer membrane protein gene (16) . In the present study, we report on a multitarget real-time PCR (MTR-PCR) assay for the detection, identification, and quantification of C. trachomatis in a single reaction. Three targets of amplification were used in this assay: the cryptic plasmid for the qualitative detection, the MOMP gene for the quantification of C. trachomatis DNA, and an internal control (IC) for the detection of inhibitors of amplification. None of the previously reported in-house or commercial assays have achieved these characteristics in a single reaction.
MATERIALS AND METHODS
Chlamydia strains. Strains of C. trachomatis from different serovars and C. suis were grown in McCoy cells, as described previously (25) . The growth of the organism was confirmed by direct immunofluorescence with a genus-specific monoclonal antibody, IMAGEN Chlamydia, according to the manufacturer's protocol (DakoCytomation Ltd., Ely, United Kingdom). McCoy cells and all strains of chlamydia were obtained from the American Type Culture Collection (ATCC), LGC Promochem, Middlesex, United Kingdom. However, C. pneumoniae was not grown in the cell culture; its DNA was obtained from Advanced Biotechnologies, Incorporated (Columbia, MD). The identities of the Chlamydia strains used in this study are shown in Table 1 .
Bacterial strains. Pathogenic bacteria and commensal organisms of the oropharynx and the genital tract were grown as described previously (1) . The suitability of bacterial DNA for amplification was checked by 16S rRNA gene-based PCR (15) . The identities of the bacterial strains used in this study are shown in Table 2 .
Validation panel. The validation panel included 146 Amplicor PCR-positive and 122 Amplicor PCR-negative samples. These samples were obtained from 56 males (urethral swabs; median age, 22 years; age range, 17 to 64 years) and 212 females (both urethral and endocervical swabs in a single tube; median age, 23 years; age range, 15 to 59 years) as described previously (12) . The samples were coded, and the results of the Amplicor PCR were masked before the validation experiments. The swab in the transport medium was agitated for 20 s at a setting of 4.5 in a multitube vortexer (model 2601; Scientific Manufacturing Industries, Emeryville, CA) before extraction of DNA. The DNA from 200 l of cell suspension (a bacterial culture or a clinical sample) was extracted by using a MagNA Pure LC total nucleic acid isolation kit and MagNA Pure LC Robot, according to the manufacturer's protocol (Roche Molecular Systems). DNA was concentrated during extraction and eluted in 100 l of elution buffer. Quality control for DNA extraction was performed by inclusion of C. trachomatis culture genotype E (positive control) and nuclease-free water (negative control) in each run.
PCR. Real-time PCR was performed with a Rotor-Gene 3000 (Corbett Robotics, Australia). Rotor-Gene has four light-emitting diodes that allow the detection of up to four targets in a single amplification reaction. This characteristic of the system was used to develop the MTR-PCR for the detection of C. trachomatis. A pair of primers and a labeled probe in the TaqMan format were used for each component of the assay, i.e., CP, MOMP, and IC. Except for the probe for the MOMP gene, the IC DNA and all primers and probes were synthesized by Metabion International AGi, Germany. The probe for the MOMP gene was obtained from Applied Biosystems, Cheshire, United Kingdom. The sequences of the primers, probes, and the internal control are shown in Table 3 . PCR was performed in a 25-l reaction mixture containing 10 l of DNA from a clinical sample or a bacterial isolate, 5 mM MgCl 2 , 12.5 l of 
Streptococcus mutans
ATCC 25175 ϩ ϩ Ϫ Ϫ Streptococcus canis ATCC 3497 ϩ ϩ Ϫ Ϫ Streptococcus sanguis ATCC 10556 ϩ ϩ Ϫ Ϫ Staphylococcus aureus ATCC 25923 ϩ ϩ Ϫ Ϫ Staphylococcus epidermidis ATCC 12228 ϩ ϩ Ϫ Ϫ Neisseria meningitidis ATCC 13077 ϩ ϩ Ϫ Ϫ Neisseria gonorrhoeae NCTC 8375 ϩ ϩ Ϫ Ϫ Escherichia coli NCTC 10418 ϩ ϩ Ϫ Ϫ Cornyebacterium ulcerans NCTC 7907 ϩ ϩ Ϫ Ϫ Pasteurella haemolytica NCTC 9380 ϩ ϩ Ϫ Ϫ Fusobacterium necrophorum NCTC 10576 ϩ ϩ Ϫ Ϫ Yersinia enterocolitica ATCC 23715 ϩ ϩ Ϫ Ϫ Cornyebacterium diptheriae ATCC 11913 ϩ ϩ Ϫ Ϫ Arcanobacterium haemolyticum NCTC 8452 ϩ ϩ Ϫ Ϫ Prevotella buccae ATCC 33574 ϩ ϩ Ϫ Ϫ Veillonella parvula ATCC 10790 ϩ ϩ Ϫ Ϫ Fusobacterium ulcerans NCTC 12111 ϩ ϩ Ϫ Ϫ Prevotella melaninogenica ATCC 25845 ϩ ϩ Ϫ Ϫ Actinobacillus actinomycetemcomitans ATCC 29522 ϩ ϩ Ϫ Ϫ Actinomyces israelii ATCC 10049 ϩ ϩ Ϫ Ϫ Clostridium difficile NCTC 11209 ϩ ϩ Ϫ Ϫ Acholeplasm laidlawii NCTC 10116 ϩ ϩ Ϫ Ϫ Mycoplasma fermentans NCTC 10117 ϩ ϩ Ϫ Ϫ Mycoplasma hyorhinis NCTC 10130 ϩ ϩ Ϫ Ϫ Mycoplasma orale NCTC 10112 ϩ ϩ Ϫ Ϫ Mycoplasma hominis NCTC 10111 ϩ ϩ Ϫ Ϫ
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Platinum Quantitative PCR SuperMix-UDG (Invitrogen Life Technologies, Paisley, United Kingdom), 6.25 pmol of each primer, and 2.5 pmol of each probe for amplification of DNA from the CP and the MOMP gene of C. trachomatis and six molecules of the IC and 2.5 pmol of each primer and probe for amplification of the IC. The IC was an artificial single-stranded DNA molecule that was designed by joining A, C, G, and T in a random order. The nucleotidenucleotide BLAST program at www.ncbi.nlm.nih.gov/BLAST/BLAST.cgi demonstrated the unique sequence of this molecule. Metabion quantified it by spectrophotometery, and the number of molecules/l was calculated by using Avogadro's number. The amplification reaction profile included heating at 50°C for 2 min and 95°C for 2 min, followed by 40 cycles of 95°C for 1 s and 60°C for 60 s. The acquisition of a signal was preformed at 60°C during each cycle. Quantification standards. Cryptic plasmid and MOMP gene copy numbers in a stock of purified DNA from C. trachomatis strain E (BOUR) were estimated by the limited-dilution, Poisson distribution method by a nested PCR (22) . The nested PCRs for the CP and MOMP genes were performed as described previously (12) . The sequences of the primers are shown in Table 3 . An external calibration curve was prepared by using serial 10-fold dilutions from the stock DNA in nuclease-free water containing 1 ng/l poly(A) RNA (Amersham Bioscience United Kingdom Ltd., Chalfont St. Giles, United Kingdom). The RotorGene software calculated the number of C. trachomatis genome copies in amplification reactions with reference to the external calibration curve. The parameters used for quantification analysis are shown in Table 4 .
Criteria for a positive result by real-time PCR. A sample was considered positive for C. trachomatis DNA if it produced signals in the channels for the CP and the MOMP components of the assay. If the signal was produced in only one of these channels, the test was repeated, in duplicate, with the DNA extract. The sample was designated positive if repeat testing confirmed the earlier finding. Otherwise, it was designated a false-positive result. The algorithm for interpretation of the assay results is shown in Fig. 1 .
Design of experiments. The lower limits of detection for the MOMP and the CP components of the assay were determined by testing a doubling dilution series of the positive control with from 25 to 0.19 genome copies per reaction mixture. The CP DNA copy number was four times greater than the MOMP gene copy number in each reaction mixture. Each concentration was tested in 40 replicates, and probit analysis of the results was carried out by using "StatsDirect," version 2.4.1 (StatsDirect, Ltd., Cheshire, United Kingdom). The analytical specificity of the assay was investigated by performing PCR with DNA from the chlamydial and bacterial strains stated in Tables 1 and 2 . Intra-and interassay reproducibilities were investigated in three different runs by using DNA from the positive control. Ten replicates of five serial 10-fold dilutions ranging from 25 to 250,000 genome copies per reaction mixture were included in each run. Intra-and interassay reproducibilities were also investigated for 14 clinical samples. A total of six replicates of each sample were included in two different runs. The results from the intra-and interassay reproducibility experiments were used to investigate the linearity and the dynamic range of the MOMP component of the assay.
RESULTS
Analytical sensitivity and specificity. According to probit analysis, the assay demonstrated a 95% probability of detection with three MOMP gene copies and one CP copy per reaction mixture. The assay was able to detect DNA from all strains of C. trachomatis listed in Table 1 . No amplicon was generated in the C. trachomatis-specific components of the assay from DNA of C. suis, C. pneumoniae, or the bacterial Table 2 ). The 16S rRNA PCR amplified DNA from all bacteria shown in Table 2 . Intra-and interassay reproducibilities and dynamic range. The results of the intra-and interassay reproducibilities for the positive controls are shown in Fig. 2 . The coefficient of variation (CV) values for across run, within run, and total variation generally increased with decreasing genome copy numbers in the reaction mixture for both the positive control and the clinical samples. The CV values for the positive control and the clinical samples are shown in Table 5 and Table 6 , respectively. The data from the intra-and interassay reproducibility experiments were used to investigate the linearity of the assay. The MOMP component of the assay exhibited a log-linear response, characteristic of levels of C. trachomatis genome input between 25 and 250,000 copies per reaction mixture. The regression line of the observed concentration to the expected concentration on a log 10 scale is shown in Fig. 3 . For this set of data, the adjusted r 2 value was 0.99 and the deviation from linearity was 0.3 log 10 .
Validation of the assay. According to the criteria stated in the Materials and Methods section, the assay detected C. trachomatis DNA from all of the 146 Amplicor PCR-positive samples. It did not detect C. trachomatis DNA from any of the 122 Amplicor PCR-negative samples. Of 146 (96%) samples, 140 generated signals in both C. trachomatis-specific components of the assay. Six samples generated a signal only in the CP component of the assay. Repeat testing confirmed the presence of CP DNA and absence of C. trachomatis genomic DNA in these samples. The assay was able to quantify the C. trachomatis load in 95 (69%) of 140 samples. The median C. trachomatis load in these samples was 321 genome copies per reaction mixture (range, 26 to 40,137 genome copies per reaction mixture). The IC was detected in all of the 268 samples and the controls. A weak signal was observed after Ͼ35 cycles of amplification in the MOMP component of the assay for one Amplicor PCR-negative sample. A similar signal was also observed in the CP component of the assay for two of the Amplicor PCR-negative samples. The signals in these three sam- ples were not detected on repeat testing and were considered nonspecific reactivity due to autohydrolysis of the probe. These samples were designated negative for C. trachomatis DNA after repeat testing.
DISCUSSION
The two previously reported in-house real-time PCR assays for the detection of C. trachomatis were qualitative in nature (8, 13) . This is the first assay that can be used for both the qualitative and the quantitative detection of C. trachomatis in clinical samples. At present, quantification of C. trachomatis is not considered valuable for the clinical management of an infection. However, it may be helpful in providing an understanding of the pathogenesis and the dynamics of the infection, i.e., the degree of infectivity, the severity of disease, the risk of developing sequelae, and the response to therapy.
There are multiple copies of CP in C. trachomatis. The majority of NAATs use it as the target for amplification to enhance the sensitivity of detection. CP is detected among all genotypes of C. trachomatis, and its nucleotide sequence is highly conserved (16) . However, a number of studies have described clinical (9, 18, 20, 24) and laboratory (14) isolates of C. trachomatis that lack CP, suggesting that it is not essential for growth of the organism. In assays targeting CP alone, there is a risk of producing false-negative results (16) , the magnitude of which is not known at present. Furthermore, CP is an inappropriate target for the quantification of C. trachomatis in clinical samples because of its variable number in the organism. Assays targeting chromosomal genes of C. trachomatis can overcome these two problems, albeit with a slightly reduced sensitivity. Six (4%) of 146 positive samples were detected by identifying the CP component of the assay only, proving its value as a target in NAATs. Thus, CP was chosen as a target for the assay described here. The MOMP gene was used to rule out the possibility of a false-negative result due to the absence of CP in C. trachomatis and to quantify the infection.
A number of studies have reported reproducibility problems with commercial NAATs for the diagnosis of C. trachomatis infection (3, 5, 6, 7, 13, 17) , and a repeat of the same assay with the initial extract or DNA newly extracted from the same sample did not improve the accuracy of diagnosis (5, 6, 13) . Since our new assay targeted two different genes of chlamydia, the presence or absence of an amplification signal in one chlamydia-specific component of the assay was confirmed by the presence or the absence of a signal in the corresponding chlamydia-specific component of the assay. Of 268 results, 259 (97%) were confirmed without repeat testing. Repeat testing was performed with nine samples due to the generation of a very weak signal in only one chlamydia-specific component of the assay. There could be two possible explanations for this phenomenon: a very low quantity of target (true weak-positive result) or autohydrolysis of the probe (false-positive result). Transposition errors and cross contamination were unlikely due to the automated extraction of the DNA in a closed system. Repeat testing of the already extracted DNA identified six of nine samples as having true-positive results and three samples as having false-positive results. Since the Amplicor assay, the reference test, confirmed these results, repeat testing was not done with the original samples. However, reextraction of DNA from the original samples may be needed if repeat testing with DNA that was already extracted is unable to resolve the true nature of a weak signal in one of the chlamydiaspecific components of the assay. All samples in the validation panel were correctly identified by the assay, which demonstrated a 100% correlation with the Amplicor PCR results. The data presented in this study have demonstrated the excellent analytical performance of the assay. However, the number of samples in the validation panel was relatively small, and validation of the assay was performed in research settings. Further work is needed to investigate the clinical performance of the assay with a much larger number of samples in a routine clinical diagnostic laboratory.
The assay detected all genovars of C. trachomatis, including genovars for lymphogranuloma venereum and trachoma. No cross-reactivity of the primers and the probes was observed for the pathogenic bacteria or the commensal organisms of the oropharynx and the genital tract. The assay demonstrated a wide dynamic range for quantification. The within-run CV was less than 6% for all dilutions with from 25 to 250,000 genome copies per reaction mixture. While the run-to-run CV was less than 19% for dilutions with from 250 to 250,000 genome copies per reaction mixture, this value was 38% for 25 genome copies per reaction mixture. The high CV for a low copy number is a common feature of all quantitative assays. Simultaneous amplification of three targets in a single reaction may have some effect on the reproducibility of the assay for quantification. No Due to the detection and confirmation of C. trachomatis DNA in a single reaction, this assay is ideally suited for laboratories with high workloads. DNA extraction and amplification are already automated in this assay. We are currently testing different platforms to automate this assay fully. Investigations are under way to evaluate its performance in comparison with that of Amplicor PCR for 1,000 consecutive patients attending a genitourinary medicine clinic. Further studies are planned to investigate the effectiveness of this assay in detecting C. trachomatis DNA in urine and rectal, pharyngeal, and eye swab specimens. Only three of the four channels available in the Rotor-Gene were used for this assay. The fourth channel could potentially be used for the detection of Neisseria gonorrhoeae, along with C. trachomatis, in the same reaction at a negligible cost. Although quality control for the DNA extraction step was performed by the inclusion of positive and negative controls, the efficiency of extraction was not monitored for individual samples. We plan to genetically engineer an Escherichia coli strain containing the unique internal control used in this assay. This strain will be used to monitor the efficiency of all steps in the assay for every individual sample.
